These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 438610)

  • 1. Serum alkaline phosphatase in azotemic and hemodialysis osteodystrophy: a study of isoenzyme patterns, their correlation with bone histology, and their changes in response to treatment with 1alphaOHD3 and 1,25(OH)2D3.
    Pierides AM; Skillen AW; Ellis HA
    J Lab Clin Med; 1979 Jun; 93(6):899-909. PubMed ID: 438610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.
    Prior JC; Cameron EC; Ballon HS; Lirenman DS; Moriarty MV; Price JD
    Am J Med; 1979 Oct; 67(4):583-9. PubMed ID: 386792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
    Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
    Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum alkaline phosphatase isoenzyme patterns in patients with chronic renal failure.
    Skillen AW; Pierides AM
    Clin Chim Acta; 1977 Oct; 80(2):339-46. PubMed ID: 912906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
    Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of uraemic osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Nielsen SP; Binderup E; Godtfredsen WO; Jensen H; Ladefoged J
    Proc Eur Dial Transplant Assoc; 1976; 12():221-6. PubMed ID: 935114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thermolability of alkaline phosphatase in the evaluation of renal osteodystrophy.
    Sagar S; Borra S; Kaye M
    Nephron; 1971; 8(3):270-7. PubMed ID: 5155279
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemodialysis patients with a unique mineralizing defect unresponsive to 1,25-dihydroxycholecalciferol. Dialysis osteomalacic syndrome.
    Cameron EC; Prior JC; Ballon HS
    Contrib Nephrol; 1980; 18():162-71. PubMed ID: 6986229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol.
    Velentzas C; Oreopoulos DG; Pierratos A; Meema HE; Rabinovich S; Meindok H; Husdan H; Murray TM; Ogilvie R; Katirtzoglou A
    Can Med Assoc J; 1981 Mar; 124(5):577-83. PubMed ID: 6894103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.
    Ahmed KY; Varghese Z; Wills MR; Meinhard EA; Moorhead JF
    Lancet; 1978 Mar; 1(8065):629-32. PubMed ID: 76168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone alkaline phosphatase isoenzyme in renal osteodystrophy.
    Jarava C; Armas JR; Salgueira M; Palma A
    Nephrol Dial Transplant; 1996; 11 Suppl 3():43-6. PubMed ID: 8840311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
    Pierides AM; Kerr DN; Ellis HA; Peart KM; O'Riordan JL; DeLuca HF
    Clin Nephrol; 1976 Apr; 3(2):189-96. PubMed ID: 819195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
    Brickman AS; Coburn JW; Sherrard DJ; Wong EG; Norman AW; Singer FR
    Contrib Nephrol; 1980; 18():29-41. PubMed ID: 7353378
    [No Abstract]   [Full Text] [Related]  

  • 16. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
    Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of alkaline phosphatase isoenzymes, bone histology, and skeletal radiography in dialysis bone disease.
    Naik RB; Gosling P; Price CP
    Br Med J; 1977 May; 1(6072):1307-10. PubMed ID: 861592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D metabolites and bone mineralization in man.
    Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
    J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of renal osteodystrophy with calciferol (vitamin D) and related steroids.
    Brickman AS; Norman AW
    Kidney Int; 1973 Aug; 4(2):161-7. PubMed ID: 4364427
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.